Myriad Genetics is to continue with the planned launch of its BRACAnalysis breast cancer susceptibility test in Europe in the next six months. However, the Salt Lake City, Utah-based company also announced that it has pulled back from a $327 million follow-on public offering on the US Nasdaq market because of the recent volatility.
In addition, Myriad plans to launch its third genetic cancer susceptibility test in the autumn, for colon cancer, to join...